Respiratory Distress SyndromePhase 2MISTCPAPNCT01723683
Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS
A Phase 2 study testing Surfactant in people with Respiratory Distress Syndrome, run by China Medical University Hospital at 1 site in Taiwan.
Trial summary
There is a reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD since the development of Surfactant therapy. A policy of intubation with surfactant administration and mechanical ventilation has become a standard therapy of infants at high risk of RDS. Read more about this study
- Who is it for?
- Ages 1 hour to 36 hours
- Conditions the study is for
- Respiratory Distress Syndrome
- What is being tested?
- Surfactant
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTaiwan
- Study dates
- Feb 2012to Jan 2013
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 hour to 36 hours
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Very preterm infants (GA < 32 wks) admitted to NICU at CMUH from 1 February 2012 to 31 January 2013 are enrolled for the study
- Less than 36 hours of age
- Clinical signs of RDS with requirement of FiO2 ≥ 0.35
Who cannot join
- Previous Intubation or in imminent need of IMV because of e.g. apnea, severe bradycardia or other deterioration not attributed to RDS, e.g. shock
- Major congenital malformations
- No parental consent
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
China Medical University Children's Hospital
Taichung, 404
Bai-Horng Su, MD, PhD, 886-4-22052121 ext. 2061, subh1168@gmail.com
About this study
Official title: Minimally Invasive Surfactant Therapy Followed by Early CPAP (MISTCPAP) in Very Preterm Infants With RDS
There is a reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD since the development of Surfactant therapy. A policy of intubation with surfactant administration and mechanical ventilation has become a standard therapy of infants at high risk of RDS. However, initial stabilization with CPAP and, if necessary, given rescue surfactant therapy has remained the standard therapy for preterm infants. Evidence reveals similar results with regard to mortality and neonatal morbidity between the above two strategies. The investigators intend to develop a method of minimally invasive surfactant therapy followed by early CPAP (MISTCPAP) in preterm Infants with high risk of RDS for improving the outcomes and reducing the incidence of BPD.
Read the detailed description
Background. Reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD has been achieved since the development of Surfactant therapy. It is also approved that initial stabilization with CPAP and rescue surfactant administration, if necessary, resulted in less ventilator days and a trend towards lower risk of CLD. However, the number of infants who are started on CPAP but ultimately require intubation for the administration of surfactant within the first 72 hours remains high in the very preterm infants. Usually CPAP failure is due to unremitting RDS requiring surfactant therapy. Outcomes in the infants with CPAP as a whole could be improved further if the subgroup of infants showing early signs of surfactant deficiency was to receive an early dose of surfactant.
Objective. This study intents to develop a method of minimally invasive surfactant therapy followed by early CPAP (MISTCPAP) in preterm Infants with high risk of RDS for improving the outcomes and reducing the incidence of BPD. We propose a prospective randomized controlled trial to compare the MISTCPAP technique with the INSURE technique of surfactant administration, which involves intubation solely for the purpose of surfactant administration followed by immediate extubation to CPAP. The outcome of this trial could declare the effect of the intubation and positive pressure ventilation on the effectiveness of surfactant therapy.
Methods. This study will be approved by the Institutional Review Board (IRB) of CMUH.Very preterm infants (GA < 32 wks) admitted to NICU at CMUH from 1 February 2012 to 31 January 2013 are enrolled for the study. Infants who stayed in the hospital for less than 10 days or those admitted after 24 hours of birth or with major congenital malformations will be excluded. Eligible infants will be randomized to allocate to the 2 groups after birth using simple randomization with sealed nontransparent envelopes after parental consent has been obtained. MISTCPAP group: The 16Gz 13 cm length Angio-Cath is used and marked at a point comparable to the level of infant's lip (weight in Kg + 6 cm as the routine ETT intubation) to give the operator mark to secure the Angio-Cath during the procedure and prevent it from going too far in or out of the trachea. The infant will be kept supine with upper part of body raised about 30 degree, an oro-gastric (OG) tube should be inserted,and the infant should not receive sedation. The CPAP may be removed transiently and the oxygen cannula or O2 flow over face may be given as indicated by saturation monitoring during the procedure. After inserting the Angio-Cath, the laryngoscope should be removed after stabilizing the Catheter with 2 fingers. Surfactant (Survanta©, Abbott, USA) 100 mg/kgBW, equivalent to 4 ml/kgBW per dose will be drawn to a 10 ml syringe and should be instillated via the Angio-Cath. Prior to the beginning of the clinical trial, every neonatal fellows should be trained to familiar the procedure under the supervision of the PI (BH Su), and the average duration of procedure has been achieved in the range of 1-3 minutes. All the vital signs, including Heart Rate, Respiratory Rate,Oxygen Saturation (SpO2) and FiO2 (Fraction of Inspired Oxygen) requirements should be monitored. After the procedure of surfactant instillation, the Angio-Cath should be removed and the nCPAP should be resumed with CPAP level keep constant at 5 cmH2O. The oro-gastric (OG) tube should be draw to check if any surfactant was instillated or reflexed back to the stomach. As to the INSURE group, the procedure should be according to the conventional surfactant treatment which involves intubation, surfactant(Survanta©, Abbott, USA) 100 mg/kgBW, equivalent to 4 ml/kgBW divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP. The clinical course in NICU of all studied infants, including intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP), duration of ventilation, duration of hospital stay, infection, duration of oxygen requirement and BPD should be recorded.
- Conditions
- Respiratory Distress Syndrome
- Being tested
- Surfactant
- Keywords
- Preterm infants, RDS, Surfactant, MISTCPAP, CPAP
- Medical subject headings
- Respiratory Distress Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SurfactantDrug
| Study group | Role | What they receive |
|---|---|---|
| MISTCPAP group | Experimental | MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP. Receives: Drug: Surfactant |
| INSURE group | Active comparator | INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP. Receives: Drug: Surfactant |
What is being measured
The primary outcome is the main question the study is designed to answer.
Requirement of rescue intubation and mechanical ventilation
Failure of MISTCPAP procedure:
SA1. Need for invasive ventilation, requiring either FiO2> 0.6 or pCO2> 65 mm Hg and pH < 7.20 or both for more than 2 hours after surfactant administration up to 72 hrs of life 2. Intubation/requirement for mechanical ventilation within 48h after first intervention (same criteria as above:requiring either FiO2> 0.6 or pCO2> 65 mm Hg and pH < 7.20 or both for more than 2 hours) 3. Acute deterioration during immediate intervention leading to intubation (e.g. severe bradycardia/resuscitation, pneumothorax)
Failure for INSURE procedure:
- Failed extubation within 15 min after intubation for surfactant application
Measured: 72 hours
Secondary outcomes (7)
1.Incidence of grade 3 /4 IVH (intraventricular hemorrhage),PVL (periventricular leucomalacia),ROP (retinopathy of prematurity) requiring treatment,NEC (necrotizing enterocolitis)stage 2 and 3
Measured: 8 weeks of life
2.Total duration of invasive and non-invasive ventilation (the extubation and weaning will follow the NICU guidelines), duration of oxygen supplementation until discharge
Measured: participants will be followed for the duration of hospital stay, an expected average of 8 weeks
3.Proportion of patients requiring oxygen supplementation at discharge 3.Proportion of patients requiring oxygen supplementation at discharge
Measured: participants will be followed for the duration of hospital stay, an expected average of 8 weeks
4.Proportion of surfactant related adverse events like tube blockade, episodes of desaturation, bradycardia, pulmonary hemorrhage, pneumothorax differ in the two groups
Measured: 1 wk of life
5.Total number of surfactant doses required compared in the two groups
Measured: 1 week of life
6.Incidence of CLD. CLD is assessed at 36 corrected weeks as NICHD definition and severity
Measured: at 36 corrected weeks
7.Death Comparison of outcomes beteween the 2 groups will use OR and 95% CIs.
Measured: 8 weeks of life
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2012 (estimated)
- Study startFeb 2012
- Primary completionJan 2013 (estimated)
- Study completionJan 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory Distress SyndromeStudies of the same condition, open and under way.
- More trials run by China Medical University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- China Medical University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Bai-Horng Su, MD, PhD, Study chair, Dept. of Pediatrics, China Medical University HospitalHsieh-Yu Lin, MD, Principal investigator, China Medical University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01723683
- Sponsor's protocol ID
- DMR101-IRB2-221
- Acronym
- MISTCPAP
- Status last verified
- Nov 2012
- First submitted
- 1 Nov 2012
- Last updated
- 8 Nov 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 8 Nov 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Minimally Invasive Surfactant Therapy Followed by Early CPAP (MISTCPAP) in Very Preterm Infants With RDS
- ClinicalTrials.gov ID
- NCT01723683
- Acronym / sponsor ID
- MISTCPAP / DMR101-IRB2-221
- Conditions
- Respiratory Distress Syndrome
- Keywords
- Preterm infants, RDS, Surfactant, MISTCPAP, CPAP
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- China Medical University HospitalUniversity, hospital or other
- Study start
- Feb 2012
- Primary completion
- Jan 2013 (estimated)
- Study completion
- Jan 2013 (estimated)
- First posted
- 8 Nov 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is a reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD since the development of Surfactant therapy. A policy of intubation with surfactant administration and mechanical ventilation has become a standard therapy of infants at high risk of RDS. However, initial stabilization with CPAP and, if necessary, given rescue surfactant therapy has remained the standard therapy for preterm infants. Evidence reveals similar results with regard to mortality and neonatal morbidity between the above two strategies. The investigators intend to develop a method of minimally invasive surfactant therapy followed by early CPAP (MISTCPAP) in preterm Infants with high risk of RDS for improving the outcomes and reducing the incidence of BPD.
Detailed description
Background. Reducing incidence of pneumothorax, PIE and the combined outcome of death or BPD has been achieved since the development of Surfactant therapy. It is also approved that initial stabilization with CPAP and rescue surfactant administration, if necessary, resulted in less ventilator days and a trend towards lower risk of CLD. However, the number of infants who are started on CPAP but ultimately require intubation for the administration of surfactant within the first 72 hours remains high in the very preterm infants. Usually CPAP failure is due to unremitting RDS requiring surfactant therapy. Outcomes in the infants with CPAP as a whole could be improved further if the subgroup of infants showing early signs of surfactant deficiency was to receive an early dose of surfactant.
Objective. This study intents to develop a method of minimally invasive surfactant therapy followed by early CPAP (MISTCPAP) in preterm Infants with high risk of RDS for improving the outcomes and reducing the incidence of BPD. We propose a prospective randomized controlled trial to compare the MISTCPAP technique with the INSURE technique of surfactant administration, which involves intubation solely for the purpose of surfactant administration followed by immediate extubation to CPAP. The outcome of this trial could declare the effect of the intubation and positive pressure ventilation on the effectiveness of surfactant therapy.
Methods. This study will be approved by the Institutional Review Board (IRB) of CMUH.Very preterm infants (GA < 32 wks) admitted to NICU at CMUH from 1 February 2012 to 31 January 2013 are enrolled for the study. Infants who stayed in the hospital for less than 10 days or those admitted after 24 hours of birth or with major congenital malformations will be excluded. Eligible infants will be randomized to allocate to the 2 groups after birth using simple randomization with sealed nontransparent envelopes after parental consent has been obtained. MISTCPAP group: The 16Gz 13 cm length Angio-Cath is used and marked at a point comparable to the level of infant's lip (weight in Kg + 6 cm as the routine ETT intubation) to give the operator mark to secure the Angio-Cath during the procedure and prevent it from going too far in or out of the trachea. The infant will be kept supine with upper part of body raised about 30 degree, an oro-gastric (OG) tube should be inserted,and the infant should not receive sedation. The CPAP may be removed transiently and the oxygen cannula or O2 flow over face may be given as indicated by saturation monitoring during the procedure. After inserting the Angio-Cath, the laryngoscope should be removed after stabilizing the Catheter with 2 fingers. Surfactant (Survanta©, Abbott, USA) 100 mg/kgBW, equivalent to 4 ml/kgBW per dose will be drawn to a 10 ml syringe and should be instillated via the Angio-Cath. Prior to the beginning of the clinical trial, every neonatal fellows should be trained to familiar the procedure under the supervision of the PI (BH Su), and the average duration of procedure has been achieved in the range of 1-3 minutes. All the vital signs, including Heart Rate, Respiratory Rate,Oxygen Saturation (SpO2) and FiO2 (Fraction of Inspired Oxygen) requirements should be monitored. After the procedure of surfactant instillation, the Angio-Cath should be removed and the nCPAP should be resumed with CPAP level keep constant at 5 cmH2O. The oro-gastric (OG) tube should be draw to check if any surfactant was instillated or reflexed back to the stomach. As to the INSURE group, the procedure should be according to the conventional surfactant treatment which involves intubation, surfactant(Survanta©, Abbott, USA) 100 mg/kgBW, equivalent to 4 ml/kgBW divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP. The clinical course in NICU of all studied infants, including intraventricular hemorrhage (IVH), retinopathy of prematurity (ROP), duration of ventilation, duration of hospital stay, infection, duration of oxygen requirement and BPD should be recorded.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| MISTCPAP group | Experimental | Drug: SurfactantMISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP. |
| INSURE group | Active comparator | Drug: SurfactantINSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP. |
Who may qualify
- Ages
- 1 hour to 36 hours
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- Very preterm infants (GA < 32 wks) admitted to NICU at CMUH from 1 February 2012 to 31 January 2013 are enrolled for the study
- Less than 36 hours of age
- Clinical signs of RDS with requirement of FiO2 ≥ 0.35
Key exclusion criteria (3 listed)
- Previous Intubation or in imminent need of IMV because of e.g. apnea, severe bradycardia or other deterioration not attributed to RDS, e.g. shock
- Major congenital malformations
- No parental consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Surfactant | Drug | INSURE group, MISTCPAP group |
Primary outcome
Requirement of rescue intubation and mechanical ventilation
Time frame: 72 hours
Failure of MISTCPAP procedure: SA1. Need for invasive ventilation, requiring either FiO2> 0.6 or pCO2> 65 mm Hg and pH < 7.20 or both for more than 2 hours after surfactant administration up to 72 hrs of life 2. Intubation/requirement for mechanical ventilation within 48h after first intervention (same criteria as above:requiring either FiO2> 0.6 or pCO2> 65 mm Hg and pH < 7.20 or both for more than 2 hours) 3. Acute deterioration during immediate intervention leading to intubation (e.g. severe bradycardia/resuscitation, pneumothorax) Failure for INSURE procedure: 1. Failed extubation within 15 min after intubation for surfactant application
7 secondary outcomes
1.Incidence of grade 3 /4 IVH (intraventricular hemorrhage),PVL (periventricular leucomalacia),ROP (retinopathy of prematurity) requiring treatment,NEC (necrotizing enterocolitis)stage 2 and 3
Time frame: 8 weeks of life
2.Total duration of invasive and non-invasive ventilation (the extubation and weaning will follow the NICU guidelines), duration of oxygen supplementation until discharge
Time frame: participants will be followed for the duration of hospital stay, an expected average of 8 weeks
3.Proportion of patients requiring oxygen supplementation at discharge 3.Proportion of patients requiring oxygen supplementation at discharge
Time frame: participants will be followed for the duration of hospital stay, an expected average of 8 weeks
4.Proportion of surfactant related adverse events like tube blockade, episodes of desaturation, bradycardia, pulmonary hemorrhage, pneumothorax differ in the two groups
Time frame: 1 wk of life
5.Total number of surfactant doses required compared in the two groups
Time frame: 1 week of life
6.Incidence of CLD. CLD is assessed at 36 corrected weeks as NICHD definition and severity
Time frame: at 36 corrected weeks
7.Death Comparison of outcomes beteween the 2 groups will use OR and 95% CIs.
Time frame: 8 weeks of life
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Nov 2012.
Related trials for Respiratory Distress Syndrome
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
RecruitingObservational study
Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ARDS
Recruiting
Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants
Surfactant, Respiratory Distress Syndrome (Neonatal)
Recruiting
REspiratory MEchanics for Delivering Individualised Exogenous Surfactant
Respiratory Distress Syndrome in Premature Infant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bai-Horng Su, MD, PhD study chair
Dept. of Pediatrics, China Medical University Hospital
Hsieh-Yu Lin, MD principal investigator
China Medical University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Surfactant in people with Respiratory Distress Syndrome, run by China Medical University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Nov 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Bai-Horng Su, MD, PhD (886-4-22052121 ext. 2061, subh1168@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Requirement of rescue intubation and mechanical ventilation (time frame: 72 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Nov 2012.